Vivos Therapeutics (VVOS) Capital Expenditures (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Capital Expenditures data on file, last reported at $18000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 85.25% year-over-year to $18000.0 in Q1 2026; TTM through Mar 2026 was $5.1 million, a 842.67% increase from a year earlier, with the FY2025 full-year figure at $5.2 million, up 812.85% from the prior year.
• Capital Expenditures for Q1 2026 stood at $18000.0, down from $4.4 million in the prior quarter.
• Over the last five years, Capital Expenditures for VVOS reached as high as $4.4 million in Q4 2025 and fell as low as -$434000.0 in Q3 2023.
• Historically, Capital Expenditures has averaged $441058.8 across 5 years, with a median of $151000.0 in 2024.
• Across the five-year window, Capital Expenditures slumped 534.0% in 2023 and surged 2551.52% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $200000.0 in 2022, then soared by 276.5% to $753000.0 in 2023, then plunged by 78.09% to $165000.0 in 2024, then jumped by 2551.52% to $4.4 million in 2025, then sank by 99.59% to $18000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $18000.0 in Q1 2026, $4.4 million in Q4 2025, and -$83000.0 in Q3 2025.